spacer
home > pmps > winter 2019 > the heart of healthcare
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Heart of Healthcare

Over the last decade, many pharmaceutical companies have moved from mass market drug development to investing in niche speciality medicines. This shift in the pharma industry has been driven by the recognition that the sector’s traditional blockbuster model had become unsustainable.

This is good news for patients with rare diseases. The rise of speciality treatments for chronic, complex, and rare conditions has seen many breakthrough treatments being brought to market and offering new hope to patients.

According to IQVIA (formerly Quintiles and IMS Health), speciality medicines have enjoyed a decade of continued growth, which has put them on course to overtake the value of spending on traditional drugs in many of the world’s biggest pharma markets by 2022.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jonathan Chapper is the CEO at CHAPPER healthcare. He joined CHAPPER healthcare in 2013 from a successful career in law, where he worked at leading city law firms, as well as in an investment bank. Jonathan brought with him a wealth of commercial and legal experience, which he now applies to the pharma industry. CHAPPER healthcare is a leading specialist wholesaler and distributor and supplies pharmaceuticals to over 60 countries worldwide.
spacer
Jonathan Chapper
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Fujifilm Announces The Introduction Of A 10 Week Cell Line Development Timeline With Its Apollo™ X Advanced Mammalian Expression System

FUJIFILM Diosynth Biotechnologies (Fujifilm), a leading Contract Development and Manufacturing Organization (CDMO) with experience in the development and manufacture of recombinant biopharmaceuticals and gene therapies, has announced the reduction of cell line development timelines with its Apollo X™ Advanced Mammalian Expression System.
More info >>

White Papers

Analysis of Biopharmaceuticals to Conform to ICHQ6B

RSSL

Worldwide, the pharmaceuticals market is anticipated to grow from more than USD 782 billion in 2011 to approach a value of just over USD 971 billion by the end of 2016, registering a CAGR of over 24%. In 2010 the average medicines expenditure per person within the UK was £271, and this is expected to increase with the ageing population. A significant and increasing proportion of these sales are protein-based biotherapeutics or biomolecules. Currently, these account for 19% of the total market, and are growing at twice the rate of traditional small molecule pharmaceuticals. It is predicted that close to 50% of the top 100 pharmaceutical products will be biomolecules by 2016. By far the largest segment of the biopharmaceutical market is the monoclonal antibody (MAb) with an estimated share of 25.6%, which corresponds to USD 51.1 billion.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement